Working to prevent illness and death from viral disease
The University at Buffalo HIV and HCV Clinical Pharmacology Laboratory at the Center of Excellence in Bioinformatics and Life Sciences was added to the Global Virus Network in 2015 as a Center of Excellence.
The University at Buffalo HIV and HCV Clinical Pharmacology Laboratory at the Center of Excellence in Bioinformatics and Life Sciences, is an internationally recognized leader in antiviral pharmacology and therapeutics and has been conducting antiviral research since the beginning of the HIV epidemic. In addition, the laboratory is a training site for numerous national and international faculty, pre-doctoral students, post-doctoral fellows and residents, provides a global antiviral proficiency testing program through an NIH contract and conducts laboratory site assessments as a component of research quality assurance and capacity building.
Dr. Gene Morse, Director of the UB Center for Integrated Global Biomedical Sciences, was appointed to the GVN Zika Virus Task Force in 2016. There is a write up about this in the GVN newsletter Virion.
The Global Virus Network (GVN) is an essential and critical defense against viral disease. It is a coalition comprised of leading virologists spanning more than 20 countries worldwide, all working to advance knowledge about how viruses make us sick and to develop drugs and vaccines to prevent illness and death. No single institution in the world has expertise in all viral areas. GVN brings the best medical virologists together to leverage individual strengths and to focus global teams of scientists on key scientific problems. The power of GVN lies in its global reach, the depth of its science, and its commitment to solving viral challenges facing the human population. No other entity exists like the GVN. The GVN has 3 main interest areas:
The GVN mission is to strengthen medical research and response to current viral causes of human disease and to prepare for new viral pandemic threats.